Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Testing Method Predicts Trauma Patient Recovery Days in Advance

By LabMedica International staff writers
Posted on 16 Feb 2026

Trauma patients with nearly identical injuries often experience very different recoveries, even when treated similarly. More...

Traditional assessments based on injury severity do not always explain why some patients develop organ failure or die while others recover. This unpredictability limits doctors’ ability to intervene early and tailor care. Now, a new study shows that analyzing molecular signals in blood can predict recovery trajectories and complications days before they appear.

Researchers at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a first-of-its-kind study using “omics” technologies, combining proteomics and metabolomics to examine biological signals in trauma patients’ blood. The team mapped molecular endotypes and recovery trajectories in more than 1,300 trauma patients over time. By analyzing patterns of proteins and metabolites, researchers were able to characterize each patient’s biological response to injury rather than relying solely on physical injury scores.

The results showed that organ failure and mortality could be predicted more accurately and efficiently using omics markers than with traditional injury-based measures. The predictive models achieved 92% accuracy and were validated in an independent cohort of more than 300 trauma patients. The findings, published in Science Translational Medicine, demonstrate that molecular profiling can reveal why patients with similar injuries experience different outcomes, enabling earlier and more precise risk assessment.

Researchers say the approach lays the groundwork for personalized trauma care in real-time emergency settings. Efforts are now underway to adapt the molecular profiling system for rapid, point-of-care testing in emergency departments and military environments. The findings are also expected to influence the design of future clinical trials, including a trial evaluating fibrinogen supplementation. Investigators believe this strategy could support the development of targeted therapies and reshape trauma treatment planning.

"Two patients often arrive in the ER with nearly identical injuries but go on to have widely divergent outcomes despite similar care,” said Mitchell Cohen, senior author and professor of surgery at CU Anschutz. “This occurs because their biologic response to injury and treatment is different. Our novel approach and modeling allows us to see those differences in real time, so we can know their biologic state, predict their trajectories and tailor their treatments in a personalized manner.”

Related Links:
CU Anschutz 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.